
Gilead Sciences (GILD) Stock
Major antiviral and cancer drugmaker. Here's the price, business snapshot, and what's worth knowing about Gilead Sciences in November 2026.
Gilead Sciences (GILD) is a large US biopharmaceutical company best known for antiviral medicines, including treatments for HIV and hepatitis, and therapies for COVID-19 and certain cancers. With a market capitalisation of about $153.96 billion, Gilead blends steady cash-generating legacy products with newer growth avenues such as cell therapies and oncology after strategic acquisitions. Investors should note the company’s reliance on a handful of high‑revenue drugs, exposure to patent expiries and pricing pressures, and the binary nature of clinical trial outcomes that can materially affect share price. Gilead pays a dividend and typically generates strong free cash flow, which can appeal to income-focused investors, but returns are not guaranteed. This summary is for educational purposes only and not personalised investment advice; consider your risk tolerance and time horizon, and consult a regulated adviser before making investment decisions.
Why It’s Moving

Gilead Faces $1.5 Billion Biktarvy Headwind in 2028 Despite Growth Pipeline
- Chief Financial Officer Andy Dickinson disclosed at an investor conference that a negotiated price adjustment for Biktarvy will result in an anticipated $1.5 billion revenue headwind starting in 2028.
- Executives outlined a strategic pivot toward HIV prevention drugs and a potential new cell therapy for multiple myeloma to drive growth beyond the current Biktarvy dependency.
- The company recently completed a new Research Center in Foster City, California, designed to accommodate evolving scientific needs and support the development of inflammation and oncology pipelines.

Gilead Faces $1.5 Billion Biktarvy Headwind in 2028 Despite Growth Pipeline
- Chief Financial Officer Andy Dickinson disclosed at an investor conference that a negotiated price adjustment for Biktarvy will result in an anticipated $1.5 billion revenue headwind starting in 2028.
- Executives outlined a strategic pivot toward HIV prevention drugs and a potential new cell therapy for multiple myeloma to drive growth beyond the current Biktarvy dependency.
- The company recently completed a new Research Center in Foster City, California, designed to accommodate evolving scientific needs and support the development of inflammation and oncology pipelines.
Six-Month Growth Performance
When is the next earnings date for GILEAD SCIENCES INC (GILD)?
Gilead Sciences has not yet announced a confirmed date for its next earnings report. Based on the historical reporting pattern, which typically occurs approximately three months after the previous release, the upcoming announcement is expected in early February 2027. This report will cover the company's fourth quarter and full-year fiscal results for 2026. Investors should monitor official channels for the precise scheduling of this anticipated disclosure.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Gilead's stock with a target price of $136.67, indicating potential growth.
Financial Health
Gilead Sciences is performing well with strong revenue and profits, supported by healthy cash flow.
Dividend
Gilead Sciences' dividend yield of 1.91% is reasonable, but not very high. If you invested $1000 you would be paid $19.10 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Antiviral Franchise
Strong HIV and hepatitis drugs deliver predictable revenues, though sales can be affected by competition and patent expiries.
Oncology & Cell Therapy
Newer programmes and acquisitions expand growth potential, but clinical and regulatory outcomes can be binary and affect valuations.
Cash Flow & Dividend
Solid cash generation supports a dividend and buybacks, yet income investors should remember dividends can change and are not guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
